CIO Spotlight

Brian Schiro, MD
Hepatopulmonary shunting is a significant concern for practitioners of interventional oncology, as excessive shunting can result in complications such as radiation pneumonitis. There are a variety of strategies for managing these shunts in patients who hope to be treated with radioembolization. In… Read More
liver
Treatment with yttrium 90 (Y90) is an integral part of the practice of interventional oncology. Practitioners experienced with these procedures, as well as those entering the field, must navigate the decision of when to recommend treatment and how to ensure the procedure is carried out safely and… Read More
Daniel Sze, MD
In this Q&A, Daniel Sze, MD, PhD, discusses the results of SIRFLOX, FOXFIRE, and FOXFIRE Global trials and how continued investigations in this area, as well as in immunotherapy, may impact the field. Dr. Sze is a Professor of Radiology at Stanford University Medical Center in California, and… Read More
Dan Brown, MD
In this interview with Interventional Oncology 360, Daniel Brown, MD, FSIR, chief of interventional oncology at Vanderbilt University, discusses recent changes to his practice. He also comments on the results of the FOXFIRE Global study and how results from future studies may lead to a paradigm… Read More
Interventional oncology is a rapidly advancing field for interventional radiologists. These image-guided and minimally invasive procedures are increasing patient quality of life through easier recoveries with less burdensome procedures, including chemoembolization, Y90 therapies, radioembolization… Read More
Interventional Oncology Imaging
Clinical Interventional Oncology Course Director Ripal Gandhi, MD, Miami Cardiac and Vascular Institute (MCVI), shared his thoughts on the 9th annual Symposium in Hollywood Florida, Feb. 4-5, 2017. Tell us about the growing importance of IO and the opportunities for those interested in this… Read More
Karen Brown, MD
Many interventional oncologists are exploring combined therapies for solitary hepatocellular cancer (HCC). The outcome of combining transarterial chemoembolization (TACE) and ablation has been reported, including two randomized, controlled trials; a small trial from 20101 in which the rate of local… Read More
Interventional oncology (IO) represents the possibility of a paradigm shift in cancer therapy. Replacing surgical therapy with non-surgical options for cure, and challenging the orthodoxy of systemic chemotherapy for the control of metastatic disease, IO, while still in its relative infancy,… Read More
Drug Development Timeline
Alda Tam, MDDr Alda Tam presented the session Understanding the Role of Biopsy at the 2017 Clinical Interventional Oncology Symposium. In this article, Dr Tam provides the reader with a full deciphering of her presentation. Here she explains the role of biopsy in the drug development timeline, the… Read More